Buy the Books
Written in Frustration and The Story of a Remarkable Medicine


1. Agarwal, S. L. and Bhargava, V., Effect of drugs on brain acetylcholine levels in rats, Indian J. Med. Res., 52: 1179-1182, 1964.

2. Alarcon-Segovia, D., Wakim, K. G., Worthington, J. W., and Ward, L. E., Clinical and experimental studies on the bydralazine syndrome and its relationship to systemic lupus crythematosus, Medicine, 46: 1-33, 1967.

3. Alvarez, W. C., Pseudo-ulcer, Gastroenterology, 14: 321-323, 1950.

4. Alvarez, W. C., “Why, that’s our Jimmy,” Mod. Med., 75-76, 1968.

5. Aring, C. D., Management of fits in adults, Ohio Med. J., 37: 225-230, 1941.

6. Aston, R. and Domino, E. F., Differential effects of phenobarbital, pentobarbital and diphenylhydantoin on motor cortical and reticular thresholds in the rhesus monkey, Psychopharmacologia, 2: 304-317, 1961.

7. Baer, P. N., Davis, R. K., and Merrit, A. D., Studies on Dilantin hyperplastic gingivitis: the role of magnesium, J. Dent. Res., 44: 1055, 1965.

8. Baldwin, R. W. and Kenny, T. J., Medical treatment of behavior disorders, Learning Disabilities, J. Hellmuth, Ed., 2: 313-327, Special Child Publications of The Seattle Seguin School, Inc., Seattle, 1966.

9. Baxi, S. M., Trigeminal neuralgia: treatment with diphenylhydantoin, Antiseptic, 58: 329-330, 1961.

10. Becker, R. and Balshiisernann, T., Treatment of facial pain, Deutsch Med. Wschr., 90: 2014-2020, 1965.

11. Putnam, T. J. and Merritt, H. H., Experimental determination of the anticonvulsant properties of some phenyl derivatives, Science, 85: 525-526, 1937.

12. Belton, N. R., Etheridge, J. E., Jr., and Millichap, J. G., Effects of convulsions and anticonvulsants on blood sugar in rabbits, Epilepsia, 6: 243-249,1965.

13. Bente, D., Schönhärl, E., and Krump-Erlangen, J., Electroencephalographic findings in stutterers and their application to medical therapy, Archiv für Ohren-, Nasen- und Kehlkopfheilkunde, 169: 513-519,1956.

14. Bergouignan, M., Fifteen years of therapeutic trials in essential trigeminal neuralgia: the place of diphenylhydantoin and its derivatives, Rev. Neural. (Paris), 98: 414-416, 1958.

15. Bergouignan, M., Successful cures of essential facial neuralgias by sodium diphenylhydantoinate, Rev. Laryng. (Bordeaux), 63: 34-41, 1942.

16. Bergouignan, M. and d’Aulnay, N., Effects of sodium diphenylhydantoin in essential trigeminal neuralgia, Rev. Otoneuroopthal. (Paris), 23: 427-431, 1951.

17. Bernsohn, L., Possley, L., and Custod, J. T., Alterations in brain adenine nucleotides and creatinine phosphate in vivo after the administration of chlorpromazine, JB-516, Dilantin and RO 5-0650 (Librium), Pharmacologist, 2: 67, 1960.

18. Bernstein, H., Gold, H., Lang, T. W., Pappelbaum, S., Bazika, V., and Corday, E., Sodium diphenylhydantoin in the treatment of recurrent cardiac arrhythmias, JAMA, 191: 695-697, 1965.

19. Bigger,j. T.,Jr., Bassett, A. L., and Hoffman, B. F., Electrophysiological effects of diphenylhydantoin on canine Purkinje fibers, Circ. Res., 22: 221-236, 1968.

20. Bigger, J. T., Jr., Harris, P. D., and Weinberg, D. I., Effects of diphenylhydantoin on cardiac conduction and repolarization, Amer. J. Cardiol., 19: 119-120, 1967.

21. Bigger, 1. T., Jr., Schmidt, D. H., and Kutt, H., The relationship between the antiarrhythmic effect and the plasma level of diphenylhydantoin sodium (Dilantin), Bull. N.Y. Acad. Med., 42:1039,1966.

22. Bigger, J. T., Jr., Strauss, H. C., and Hoffmann, B. F., Effects of diphenylhydantoin on atrioventricular conduction, Fed. Proc., 27: 406, 1968.

23. Blatrnan, S. and Metcalf, D. R., Abnormal electroencephalograms in asthmatic children, Amer. J. Dis, Child., 102: 531, 1961.

24. Blaw, M. E. and Torres, F., Treatment of pseudoretardation associated with epilepsy, Mod. Treatm., 4: 799-816, 1967.

25. Bodkin, L. G., Oral therapy for pruritus ani, Amer. J. Dig. Dis., 12: 255-257, 1945.

26. Bodkin, L. G., Pruritus ani: a review of oral therapy, Amer. Dig. Dis., 14: 109-113, 1947.

27. Boelhouwer, C., Henry, C. E., and Glueck, B. C., Positive spiking: a double blind control study on its significance in behavior disorders, both diagnostically and therapeutically, Amer. J. Psychiat., 125: 473-481, 1968.

28. Bogoch, S., Diphenylhydantoin: therapeutic uses and mechanisms of action, Dreyfus Medical Foundation, 1968.

29. Booker, H. E., Matthews, C. G., and Slaby, A., Effects of diphenylhydantoin on physiological and psychological measures in normal adults, Neurology, 17: 949-951, 1967.

30. Bose, B. C., Saifi, A. Q., and, Sharma, S. K., Studies on anticonvulsant and antifibrillatory drugs, Arch. Int. Pharmacodyn., 146: 106-113, 1963.

31. Braham, J. and Saia, A., Phenytoin in the treatment of trigeminal and other neuralgias, Lancet, 2: 892-893, 1960.

32. Braverman, 1. M., and Levin, J., Dilantin-induced serum sickness: case report and inquiry into its mechanism, Amer. J. Med., 35: 418-422, 1963.

33. Bray, P. F., Diphenylhydantoin (Ditantin) after 20 years: a review with re-emphasis by treatment of 84 patients, Pediatrics, 23: 151-161, 1959.

34. Brennan, R. W., Dehejia, M., Kutt, H., and McDowell, F., Diphenylhydantoin intoxication attendant to slow inactivation of isoniazid, Neurology, 18: 183, 1968.

35. Brill, N. Q., and Walker, E. F., Psychopathic behavior with latent epilepsy, J. Nerv. Ment. Dis., 101: 545-549, 1945.

36. Brittingbam, T. E., Lutcher, C. L., and Murphy, D. L., Reversible erythroid aplasia induced by diphenylhydantoin, Arch. Intern. Med., 113: 764-768, 1964.

37. Broddle, W. D. and Nelson, S. R., The effect of diphenylhydantoin on energy reserve levels in brain, Fed. Proc., 27: 751, 1968.

38. Brown, W. T. and Solomon, C. I., Delinquency and the electroencephalograph, Amer. J. Psychiat., 98: 499-503, 1942.

39. Buchthal, F. and Svensmark, O., Aspects of the pharmacology of Phenytoin (Dilantin) and phenobarbital relevant to their dosage in the treatment of epilepsy, Epilepsia, 1: 373-384, 1959-1960.

40. Burke, E. C. and Peters, G. A., Migraine in childhood: a preliminary report, A.M.A. J. Dis. Child., 92: 330-336, 1956.

41. Byrne, J. E. and Dresel, P. E., A model for evaluating drugs which prolong post-countershock periods of normal sinus rhythm (NSR), Pharmacologist, 10: 220, 1968.

42. Cameron, A. J., Baron, J. H., and Priestley, B. L., Erythema multiforme, drugs, and ulcerative colitis, Brit. Med. J., 2: 1174-1178, 1966.

43. Campbell, E. W., Jr., and Young, J. D., Jr., Enuresis and its relationship to electroencephalographic disturbances, J. Urol., 96: 947-949, 1966.

44. Cantu, R. C. and Schwab, R. S., Ceruloplasmin rise and PBI fall in serum due to diphenylhydantoin, Arch. Neurol., 15: 393-396, 1966.

45. Cantu, R. C., Schwab, R. S., and Timberlake, W. H., Comparison of blood levels with oral and intramuscular diphenylhydantoin, Neurology, 18: 782-784, 1968.

46. Case, W. G., Rickels, K., and Bazilian, S., Diphenylhydantoin in neurotic anxiety, Amer. J.,Psychiat., 126: 254-255, 1969.

47. Caspers, H. and WehmeyLr, H., The action of diphenylhydantoin on the seizure threshold of the brain, Z. Ges. Exp. Med., 129: 77-86, 1957.

48. Caveness, W., Adams, R. D., Pope, A., and Wegner, W. R., The role of the dorsal root ganglia in the production of the lancinating pains of central nervous system syphilis, Trans. Amer. Neurol. Assn., 60-64, 1949.

49. Chaiken, B. H., Goldberg, B. I., and Segal, J. P., Dilantin sensitivity: report of a case of hepatitis with jaundice, pyrexia and exfoliative dermatitis, New Eng. J. Med., 242: 897-898, 1950.

50. Chang, T. and Glazko, A. J., Quantitative assay of 5,5’-diphenylhydantoin (Dilantin) and 5-(4-hydroxyphenyl)-5’-phenylhydantoin by gas-liquid chromatography, Clin. Res., 16: 339, 1968.

51. Chao, D., Sexton, J. A., and Davis, S. D., Convulsive equivalent syndrome of childhood, J. Pediat, 64: 499-508, 1964.

52. Chenoweth, M. B., Clinical uses of metal binding drugs, Chn.,Pharm”ol. Ther., 9: 365-387, 1968.

53. Childress, R. H., Higgs, L. M., Boyd, D. L., and Williams, J. F.,Jr., Effect of diphenylhydantoin on left ventricular function in patients with heart disease, Circulation, 33-34: 73, 1966.

54. Chinitz, A., Seelinger, D. F., and Greenhouse, A. H., Anticonvulsant therapy in trigeminal neuralgia, Amer. J. Med. Sci., 252: 62-67, 1966.

55. Christensen, K., On the preparation and stability of Phenytoin solutions for injection, Dansk Tidsskr. Farm., 34: 97-109, 1960.

56. Chung, A. C., The influence of diphenyihydantoin (Dilantin) on the development of atherosclerosis in rabbits, J. Atheroscler. Res., 7: 373-379, 1967.

57. Chung, A. C., Duren, B. Y., and Houck, J. C., Effect of diphenylhydantoin administration upon concentration of liver and aortic lipids, Proc. Soc. Exp. Biol. Med., 110: 788-789, 1962.

58. Cohen, H. B., Duncan, R. F., 11, and Dement, W. C., The effect of diphenylhydantoin and sleep in the cat, Electroenceph. Clin. Neurophysiol., 24: 401-408, 1968.

59. Cohen, H. D. and Barondes, S. H., Puromycin effect on memory may be due to occult seizures, Science, 157: 333-334, 1967.

60. Cole, J. O. and Davis, J. M., Brief report of papers on diphenylhydantoin in plenary session, American College of Neuropsychopharmacology, fifth annual meeting, Psychopharm. Bull. 4: 28-31, 1967.

61. Conn, R. D., Diphenylhydantoin sodium in cardiac arrhythmias, New Eng. J. Med., 272: 277-282, 1965.

62. Conn., R. D., New drugs for old hearts: newer antiarrhythmic and diuretic agents, Postgrad. Med. 42: 71-79, 1967.

63. Corday, E., Lang, T. W., Bazika, V., and Pappelbaurn, S., Antiarrhythmic acts directly on myocardium, JAMA, 193: 28, 1965.

64. Cox, A. R., Pitt, W., Brown, T. C. K., and Molaro, A., Antiarrhythmic action of diphenylhydantoin (Dilantin) studied in isolated cardiac tissue, Canad. Med. Assn. J., 94: 661, 1966.

65. Crawford, S. E. and Jones. C. K., Fatal liver necrosis and diphenylhydantoin sensitivity, Pediatrics, 30: 595-600, 1962.

66. Crue, B. L., Jr., Alvarez-Carregal, E., and Todd, E. M., Neuralgia: consideration of central mechanisms, Bull. Los Angeles Neurol. Soc., 29: 107-132, 1964.

67. Crue, B. L., Jr., Todd, E. M., and Duemler, L. P., Pain as sensory epilepsy, Bull. Los Angeles Neurol. Soc., 32: 53, 1967.

68. Crue, B. L., Jr., Todd, E. M., and Loew, A. G., Clinical use of mephenesin carbamate (Tolserarn) in trigeminal neuralgia, Bull. Los Angeles Neural. Soc., 30; 212-215, 1965.

69. Cucinell, S. A., Factors affecting drug metabolism, Bull. N.Y. Acad. Med., 42: 324, 1966.

70. Popek, K., Czechs make anticonvulsants a must for coma victims, Med. World News, 33, March 8, 1968.

71. Dab], J. R., Diphenylhydantoin toxic psychosis with associated hyperglycemia, Calif. Med., 107: 345-347, 1967.

72. Dam, M., Organic changes in Phenytoin intoxicated pigs, Acta Neurol. Scand., 42: 491-494, 1966.

73. Dam, M. and Olesen, V., Intramuscular administration of Phenytoin, Neurology, 16: 288-292, 1966.

74. Dayton, P. G., Cucinell, S. A., Weiss, M., and Perel, J. M., Dose dependence of drug plasma level decline in dogs, J. Pharm. Exp. Ther., 158: 305-316,1967.

75. de la Vega, P., Clinical results of the treatment of Sydenham’s chorea with sodium diphenylhydantoin, Rev. Clin. Esp. 24: 113-115, 1947.

76. Dill, R. E., Discrepancy of adrenal responses in diphenylhydantoin treated rats, Arch. Int. Pharmacodyn., 160: 363-372, 1966.

77. Dill, W. A., Kazenko, A., Wolf, L. M., and Glazko, A. J., Studies on 5,5’-diphenylhydantoin (Dilantin) in animals and man, J. Pharm. Exp. Ther., 118: 270-279, 1956.

78. Dimsdale, H., Migraine, Practitioner, 198: 490-494, 1967.

79. Dixon, R. L., The interaction between various drugs and methotrexate, Toxic. Appl. Pharmacol., 12: 308, 1968.

80. Dorph, M., Coronary care units and the aggressive management of acute myocardial infarction, Delaware Med. J. 44-48, February, 1968.

81. Dorsey, J. F., Haystip, G. W., and Anderson, K., Tic douloureux: treatment with diphenylhydantoin, Clin. Med., 6: 13951397, 1959.

82. Dreifus, L. S., Rabbino, M. D., and Watanabe, V., Newer agents in the treatment of cardiac arrythmias, Med. Clin. N. Ame,r., 48: 371-387, 1964.

83. Druskin, M. S., Anticonvulsants and anemia, Clin. Med., 71: 1911-1916, 1964.

84. I)ruskin, M. S., Wailen, M. H., and Bonagura, L., Anticonvulsant associated megaloblastic anemia: response to 25 microgm. of folic acid administered by mouth daily, New Eng. J. Med., 267: 483-485, 1962.

85. Dubois, E. L., Toxic hepatic necrosis associated with taking Dilantin, Tridione and phenobarbital, Amer. J. Clin. Path., 20: 153-158, 1950.

86. Duma, R. J., Hendry, C. N., and Donahoo, J. S., Hypersensitivity to diphenylhydantoin (Dilantin): a case report with toxic hepatitis, Southern Med. J., 59: 168-170, 1966.

87. Dutton, P., Phenytoin toxicity with associated meningeal reactions. J. Ment. Sci., 104: 1165-1166, 1958.

88. Eissner, H., Diphenylhydantoin exanthema in the form of infectious mononucleosis, Arch. Toxik., 18: 282-295,1960.

89. Endröczi, E. and Fekete, T., Amino acid composition of the Ammon’s horn and the effect of anticonvulsant drugs, Acta Physiol. Acad. Sci. Hung., 32: 389-398, 1967.

90. Esplin, D. W., Effects of diphenylhydantoin on synaptic transmission in cat spinal cord and stellate ganglion, J. Pharm. Exp. Ther., 120: 301-323, 1957.

91. Fabrykant, M., Further studies on electrocerebral dysfunction and the use of anticonvulsants in labile diabetes, Ann. Intern. Med., 38: 814-823, 1953.

92. Fabrykant, M. and Pacella, B. L., Labile diabetes: electroencephalographic status and effect of anticonvulsive therapy, Ann. Intern. Med., 29: 860-877, 1948.

93. Ferngren, H. and Paalzow, L., Studies on electrically induced seizures and their antagonism by anticonvulsants during neonatal development in the mouse, Acia Pharinaeol. Toxicol., 25: 60, 1967.

94. Festoff, B. W. and Appel, S. H., Effect of diphenylhydantoin on synaptosome sodium-potassium-ATPase, J. Clin. Invest., 47: 2752-2758, 1968.

95. Fetterman, J. L. and Shallenberger, W. D., Further studies in Dilantin sodium therapy of epilepsy, Dis. Nerv. System, 2: 383-389, 1941.

96. Fichman, M. P. and Bethune, J. E., The role of adrenocorticoids in the inappropriate antidiuretic hormone syndrome, Ann. Intern. Med., 68: 806-820, 1968.

97. Fichman, M. P., Kleeman, C. R. and Bethune, Inhibition of antidiuretic hormone secretion by diphenylhydantoin, Arch. Neurol., 22: 45-53, 1970.

98. Finch, E. and Lorber, J., Methaemoglobinaemia in the newborn: probably due to Phenytoin excreted in human milk, Obstet. Gynaec. Brit. Emp., 61: 833-834, 1954.

99. Fink, G. B. and Swinyard, E. A., Comparison of anticonvulsant and psychopharmacologic drugs, J. Pharm. Sci., 51: 548-551, 1962.

100. Finkelman, 1. and Arieff, A. J., Untoward effects of Phenytoin sodium in epilepsy, JAMA, 118: 1209-1212, 1942.

101. Firemark, H., Barlow, C. F., and Roth, L. J., The entry, accumulation and binding of diphenylhydantoin-2-C14 in brain: studies on adult, immature and hypercapnic cats, Int. J. Neuropharmacol, 2: 25-38, 1963.

102. Fishbeck, R. and Zucker, G., Phenytoin (5,5-diphenylhydantoin) hypersensitivity presenting a clinical picture of scarlatiniform erythroderma, Deutsch. Gesundh., 21; 1273-1277, 1966.

103. Floyd, F. W., The toxic effects of diphenylhydantoin: a report of 23 cases, Clin. Proc. Child Hosp., D. C., 17: 195-201, 1961.

104. Forshaw, J. W. B., Megaloblastic anemia associated with anticonvulsant therapy, Postgrad. Med. J. (London), 33: 242-243, 1957.

105. Fox, V., Treatment of the non-neurologic complications of alcoholism, Mod. Treatm., 3: 502-508, 1966.

106. Frankel, S. I,. Dilantin sodium in the treatment of epilepsy, JAMA,114: 1320-1321, 1940.

107. Frantzen, E., Hansen, J. M., Hansen, O. E., and Kristensen, M., Phenytoin (Dilantin) intoxication, Acta Neurol Scand., 43: 440-446, 1967.

108. Freed, L. F., The psychopath: a social challenge, Med. Proc., 13: 408-414, 1967.

109. Frey, H. H., Kampmann, E., and Nielsen, C. K., Study on combined treatment with phenobarbital and diphenylhydantoin, Arta Pharmacol. Toxic., 26: 284-292, 1968.

110. Freyhan, F. A., Effectiveness of diphenylhydantoin in management of nonepileptic psychomotor excitement states, Arch. Neurol. Psychiat., 53: 370-374, 1945.

111. Friedman, A. P., The migraine syndrome, Bull. N.Y. Acad. Med., 44: 45-62, 1968.

112. Friedman, A. P. and Merritt, H. H., Treatment of headache, JAMA, 163: 1111-1117, 1957.

113. Gabka, J., On the therapy of idiopathic and symptomatic head and facial pains, Med. Mschr., 17: 430-443, 1963.

114. Galindo, A. M. and Ginabreda, J. M. S., Treatment of chorea minor with diphenylhydantoin sodium, Ann. Med. (Barcelona), 34: 165-168, 1947.

115. Garouette, J. V., A suggested mechanism of action for the anticonvulsant properties of diphenylhydantoin, Tulane U. Med. Fac. Bull., 24: 319-328, 1965.

116. Gatenby, P. B. B., Anticonvulsants as a factor in megaloblastic anemia in pregnancy, Lancet, 2: 1004-1005, 1960.

117. Gautray, J. P. and Natter, S., The significance of EEG and of neuro-sedative therapies in the gynecology clinic, Ann. Endocr., 22: 173-185, 1961.

118. Gayet-Hallion, T. and Bertrand, I., Favorable action of diphenylhydantoin on the resistance of rats to drowning, Compt. Rend. Soc. Biol., 153: 757-759,1959.

119. Gellerman, G. L. and Martinez, C., Fatal ventricular fibrillation following intravenous sodium diphenylhydantoin therapy, JAMA, 200: 337-338, 1967.

120. Gellman, V., A case of diphenylhydantoin (Dilantin) intoxication, Manitoba Med. Rev., 46: 388-390, 1966.

121. Gershbein, L. L., Effect of drugs and catecholamines on rat diaphragm carbohydrate metabolism, J. Pharm. Sci., 55: 846-848,1966.

122. Gilbert, J. C., Ortiz, W. R., and Millichap, J. G., The effects of anticonvulsant drugs on the permeability of brain cells to D-xylose, J. Neurochem., 13: 247-255, 1966.

123. Golbert, T. M., Sanz, C. J., Rose, H. D., and Leitschuh, T. H., Comparative evaluation of treatments of alcohol withdrawal syndromes, JAMA, 201: 99-102, 1967.

124. Goldschlager, A. W. and Karliner, J. S., Ventricular standstill after intravenous diphenylhydantoin, Amer. Heart J., 74: 410-412, 1967.

125. Goldstein, N., Leider, M., and Baer, R. L., Drug eruptions from anticonvulsant drugs, Arch. Derm., 87: 612-617, 1963.

126. Gordon, P., Diphenylhydantoin and procainamide normalization of suboptimal learning behavior, Recent Advances Biol. Psychiat., 10: 121-133, 1968.

127. Goodwin, F. B., Oral therapy in anogenital pruritus, J. Nat. Proct. Assn., 18: 84-87, 1946.

128. Granick, S., The induction in vitro of the synthesis of 8-aminolevulinic acid synthetase in chemical porphyria: a response to certain drugs, sex hormones, and foreign chemicals, J. Biol. Chem., 241: 1359-1375, 1966.

129. Green, J. B., Dilantin in the treatment of lightning pains, Neurology, 11: 257-258, 1961.

130. Green, J. B., Electroencephalographic findings in a case of acute reaction to Dilantin, Electroenceph. Clin. Neurophysiol., 20: 201-202, 1966.

131. Gretter, T. E., Danner, P. K., Nibbelink, D. W., Green, D., and Sahs, A. L., The effect of diphenylhydantoin (Dilantin) on acute intermittent porphyria, Trans. Amer. Neurol. Assn., 88: 176-178,1963.

132. Grissom, J. H., Sy, B. G., Duffy, J. P., and Dunea, G., Dangerous consequence from use of Phenytoin in atrial flutter, Brit. Med. J., 4: 34, 1967.

133. Gropper, A. L., Diphenylhydantoin sensitivity: report of fatal case with hepatitis and exfoliative dermatitis, New Eng. J. Med., 254: 522-523,1956.

134. Grosz, H. J., Dilantin intoxication-with a report of one case, Amer. Pract. Dig. Treatm., 7: 1633-1636, 1956.

135. Gupta, R. C. and Kofoed, J., Toxicological statistics for barbiturates, other sedatives, and tranquilizers in Ontario: a 10 year survey, Canad. Med. Assn. J., 94: 863-865, 1966.

136. Gydell, K., Megaloblastic anemia in patients treated with diphenylhydantoin and primidone, Acta Haemat., 17: 1-15, 1957.

137. Hamfelt, A., Killander, A., Malers, E., and de Verdier, C., Megaloblastic anemia associated with anticonvulsant drugs, Acta Med. Scand., 177: 549-555, 1965.

138. Hansen, J. M., Kristensen, M., Skovsted, L., and Christensen, L. K., Dicoumarol-induced diphenylhydantoin intoxication, Lancet, 2: 265-266, 1966.

139. Hansen, H. A., Nordqvist, P., and Sourander, P., Megaloblastic anemia and neurologic disturbances combined with folic acid deficiency: observations on an epileptic patient treated with anticonvulsants, Acta Med. Scand., 176: 243-251, 1964.

140. Harinasuta, U. and Zimmerman, H. J., Diphenylhydantoin sodium hepatitis, JAMA, 203: 1015-1018, 1968.

141. Harris, A. S. and Kokernot, R. H., Effects of diphenylhydantoin sodium (Dilantin sodium) and phenobarbital sodium upon ectopic ventricular tachycardia in acute myocardial infarction, Amer. J. Physiol, 163: 505-516, 1950.

142. Harris, J. and Ritchie, K., Anticonvulsant effects on copper uptake by neural tissue, Fed. Proc., 25: 2091, 1966.

143. Harris, P. D., Bigger, J. T., J r., Weinberg, D., and Malm, R., Use of diphenylhydantoin in ventricular arrhythmias following open heart surgery, Surg. Forum, 17: 185-188, 1966.

144. Hartmann, J. F., High sodium content of cortical astrocytes: electron microscope evidence, Arch. Neurol, 15: 633-642, 1966.

145. Hatzmann, I., Neuhold, R., and von Rittner, W., Exfoliative dermatitis after hydantoin therapy, Ann. Pediat. (Basel), 179: 305-316,1952.

146. Hausser, E., Bergoz, R. and Croci, D., Megaloblastic anemia provoked by antiepileptic medications, Nouv. Rev. Franc. Hemat., 4: 221-232, 1964.

147. Hawkins, C. F. and Meynell, M. J., Macrocytosis and macrocytic anemia caused by anticonvulsant drugs, Quart. J. Med., 27: 45-63, 1958.

148. Hawkins, C. F. and Meynell, M. J., Megaloblastic anemia due to Phenytoin sodium, Lancet, 2: 737-738, 1954.

149. Helfant, R. H., Scherlag, B. J., and Damato, A. N., The comparative electrophysiological effects of diphenylhydantoin and procaine amide in the digitalis intoxicated and nondigitalized heart, Clin. Res., 15: 206, 1967.

150. Helfant, R. H., Scherlag, B. J., and Damato, A. N., The use of diphenylhydantoin in ventricular arrhythmias unresponsive to procaine amide: a dissociation of procaine amide’s actions on automaticity and conduction, Circulation, 36: 139, 1967.

151. Helfant, R. H., Scherlag, B. J., and Damato, A. N., Diphenylhydantoin prevention of arrhythmias in the digitalis-sensitized dog after direct-current cardioversion, Circulation, 37: 424-428, 1968.

152. Helfant, R. H., Scherlag, B. J., and Damato, A. N., Diphenylhydantoin toxicity, JAMA, 201: 894, 1967,

153. Helfant, R. H., Scherlag, B. J., and Damato, A. N., Electrophysiological effects of direct current countershock before and after ouabain sensitization and after diphenylhydantoin desensitization in the dog, Circ. Res., 22: 615-623, 1968.

154. Helfant, R. H., Scherlag, B. J., and Damato, A. N., The electrophysiological properties of diphenylhydantoin sodium as compared to procaine amide in the normal and digitalis intoxicated heart, Circulation, 36: 108-118, 1967.

155. Helfant, R. H., Scherlag, B. J., and Damato, A. N., Protection from digitalis toxicity with the prophylactic use of diphenylhydantoin sodium: an arrhythmic-inotropic dissociation, Circulation, 36: 119-124, 1967.

156. Helfant, R. H., Scherlag, B. J., and Damato, A. N., Use of diphenylhydantoin sodium to dissociate the effects of procaine amide on automaticity and conduction in the normal and arrhythmic heart, Amer. J. Cardiol., 20: 820-825, 1967.

157. Helfant, R. H., Ricciutti, M. A., Scherlag, B. J., and Damato, A. N., Effect of diphenylhydantoin sodium (Dilantin) on myocardial A-V potassium difference, Amer. J. Physiol., 214: 880-884, 1968.

158. Helfant, R. H., Lau, S. H., Cohen, S. I., and Damato, A. N., Effects of diphenylhydantoin on atrioventricular conduction in man, Circulation, 36: 686-691, 1967.

159. Herman, C. J. and Bignall, K. E., Effects of diphenylhydantoin on spontaneous and evoked activity in the cat under chloralose anesthesia, Electroenceph. Clin. Neurophysiol., 23: 351-359, 1967.

160. de la Herran, J., Martinez-Lage, J. M., and Molina, P., Treatment of trigeminal neuralgia with diphenylhydantoin and disulphur of pyridoxine, Medicina Clinica, 38: 375-378, 1962.

161. Hirschmann, J., On the interval treatment of migraine, Ther. Umsch., 21; 48-51, 1964.

162. Hoaken, P. C. S., and Kane, F. J., Jr., Unusual brain syndrome seen with diphenylhydantoin and pentobarbital, Amer. Psychiat., 120: 282-283, 1963.

163. Hockman, C. H., Mauck, H. P., Jr., and Chu, N., ECG changes resulting from cerebral stimulation. 111. Action of diphenylhydantoin on arrhythmias, Amer. Heart J., 74: 256-260, 1967.

164. Hoff, E. C. and Yahn, C., The effect of sodium 5,5-diphenylhydantoinate (Dilantin sodium) upon the tolerance of rats and mice to decompression. Amer. J. Physiol, 141: 7-16, 1944.

165. Hofmann, W. W., Cerebellar lesions after parenteral Dilantin administration, Neurology, 8: 210-214, 1958.

166. Holecková, R., Some experiences in treatment of cardiac arrhythmias using diphenylhydantoin, Vnitmi. Lek., 13: 1195-1196, 1967.

167. Holland, P. and Mauer, A. M., Diphenylhydantoin induced hypersensitivity reaction, J. Pediat., 66: 322-332, 1965.

168. Hopf, H. C., On the alteration of transmission function of peripheral motor nerve fibers through diphenylhydantoin, Deutsch Z. Nervenheilk, 193: 41-56, 1968.

169. Horsfield, G. 1. and Chalmers, J. N. M., Megaloblastic anemia associated with anticonvulsant therapy, Practitioner, 19 1: 316-321, 1963.

170. Horwitz, S. J., Klipstein, F. A., and Lovelace, R. E., Relation of abnormal folate metabolism to neuropathy developing during anticonvulsant drug therapy, Lancet, 1: 563-565, 1968.

171. Houck, J. C. and Patel, Y. M., Proposed mode of action of corticosteroids on the connective tissue, Nature, 206: 158-160, 1965.

172. Houck, J. C., Jacob, R. A., and Maengwyn-Davies, G. D., The effect of sodium Dilantin administration upon the chemistry of the skin, J. Clin. Invest., 39: 1758-1762, 1960.

173. Huisman, J. W., The estimation of some important anticonvulsant drugs in serum, Clin. Chim. Acta, 13: 323-328, 1966.

174. Husby, J., Delayed toxicity and serum concentrations of Phenytoin, Danish Med., Bull., 10: 236-239, 1963.

175. Iannone, A., Baker, A. B., and Morrell, F., Dilantin in the treatment of trigeminal neuralgia, Neurology, 8: 126-128, 1958.

176. Isaacs, H., A syndrome of continuous muscle-fibre activity. J. Neurol. Neuro-surg. Psychiat., 24: 319-325, 1961.

177. Isaacs, H., Quantal squander, S. A. J. Lab. Clin. Med., 10: 93-95, 1964.

178. Itil, T. M., Rizzo, A. E., and Shapiro, D. M., Study of behavior and EEG correlation during treatment of disturbed children, Dis. Nerv. Syst., 28: 731-736, 1967.

179. Jensen, B. N. and Grynderup, V., Studies on the metabolism of Phenytoin, Epilepsia, 7: 238-245, 1966.

180. Jensen, H. P., The treatment of trigeminal neuralgia with diphenylhydantoin, Arztl. Wochschr., 9: 105-108, 1954.

181. Jonas, A. D., The diagnostic and therapeutic use of diphenylhydantoin in the subictal state and non-epileptic dysphoria, Int. J. Neuropsychiat., 3: S21 -S29, 1967.

182. Jurna, I., Depression by antiparkinson drugs of reserpine rigidity, Naunyn-Schmiedeberg Arch. Pharm., 260: 80-88, 1968.

183. Jurna, I. and Regélhy, B., The antagonism between reserpine and some antiparkinson drugs in electroseizure, Naunyn-Schmiedeberg Arch. Pharm., 259: 442-459, 1968.

184. Kabat, H., Drug therapy of cerebellar ataxia and disorders of the basal ganglia, based on cerebellar-striatal antagonism, Ann. Intern. Med., 50: 1438-1448, 1959.

185. Kabat, H. and McLeod, M., Neuromuscular dysfunction and treatment in athetosis, Conn. Med., 23: 710-714, 1959.

186. Kalinowsky, L. B. and Putnam, T. J., Attempts at treatment of schizophrenia and other nonepileptic psychoses with Dilantin, Arch. Neurol. Psychiat., 49: 414-420, 1943.

187. Karliner, J. S., Intravenous diphenylhydantoin sodium (Dilantin) in cardiac arrhythmias, Dis. Chest, 51: 256-269, 1967.

188. Kelin, E. E., Further studies of an epilepsy drug, Dental Prog., 3: 271-273, 1963.

189. Kelin, E. E. and Gorlin, R. J., Healing qualities of an epilepsy drug, Dental Prog., 1: 126-129, 196 1.

190. Kemp, J. W. and Swinyard, E. A., Diphenylhydantoin inhibition of hexobarbital metabolism by liver microsomes in mice and rats, Fed. Proc., 27: 350, 1968.

191. Kertesz, A., Paroxysmal kinesigenic choreoathetosis: an entity within the paroxysmal choreoathetosis syndrome, Neurology, 17: 680-690, 1967.

192. Khan, M. T. and McEwen, H. D., Effect of diphenylhydantoins on rat uterus in vitro, Proc. Can. Fed. Biol. Soc., 10: 161, 1967.

193. Kidd, P. and Mollin, D. L., Megaloblastic anemia and vitamin-BI2 deficiency after anticonvulsant therapy: report of two cases, Brit. Med. J., 2: 974-976, 195 7.

194. Kiørboe, E., Phenytoin intoxication during treatment with antabuse (Disulfiram), Epilepsia, 7: 246-249, 1966.

195. Kiørboe, E. and Plum, C. M., Megaloblastic anemia developing during treatment of epilepsy, Acia Med. Scand., 179: suppl. 445, 349-357, 1966.

196. Klein, D. F. and Greenberg, I. M., Behavioral effects of diphenylhydantoin in severe psychiatric disorders, Amer. J. Psychiat., 124: 847-849, 1967.

197. Klipstein, F. A., Subnormal serum folate and macrocytosis associated with anticonvulsant drug therapy, Blood, 23: 68-86, 1964.

198. Krieger, D. T., Effect of diphenylhydantoin on pituitaryadrenal interrelations, J. Clin. Endocrinol. Metab., 22: 490-493, 1962.

199. Krieger, D. T. and Krieger, H. P., The effect of short-term administration of CNS-acting drugs on the circadian variation of the plasma 17-OHCS in normal subjects, Neuroendocrinology, 2: 232-246, 1967.

200. Kristensen, M., Hansen, J. M., Hansen, O. E., and Lund, V., Sources of error in the determination of Phenytoin (Dilantin) by Svensmark and Kristensen’s method, Acta Neuvol. Scand., 43: 447-450, 1967.

201. Kubanek, J. L. and Rowell, R. C., The use of Dilantin in the treatment of psychotic patients unresponsive to other treatment, Dis. Nerv. Syst., 7: 1-4, 1946.

202. Kugelberg, E. and Lindblom, U., The mechanism of the pain in trigeminal neuralgia. J. Neurol. Neurosurg. Psychiat., 22: 36-43, 1959.

203. Kurtzke, J. F., Leukopenia with diphenylhydantoin, Nerv. Ment. Dis., 132: 339-343, 1961.

204. Kutt, H., Intravenous use of diphenylhydantoin sodium, JAMA, 201: 210,1967.

205. Kutt, H., Haynes, J., and McDowell, F., The effect of phenobarbital upon diphenyihydantoin metabolism in man, Neurology, 15: 274-275, 1965.

206. Kutt, H., Louis, S., and McDowell, F., Intravenous diphenylhydantoin in experimental seizures: 1. Correlation of dose, blood, and tissue level in cats, Arch. Neurol., 18: 465-471, 1968.

207. Kutt, H. and McDowell, F., Management of epilepsy with diphenylhydantoin sodium: dosage regulation for problem patients, JAMA, 203: 969-972, 1968.

208. Kutt H., Winters, W., and McDowell, F., Depression of parahydroxylation of diphenylhydantoin by antituberculosis chemotherapy, Neurology, 16: 594-602, 1966.

209. Kutt, H., Winters, W., and McDowell, F., Determination of diphenylhydantoin and phenobarbital metabolites, Fed. Proc., 23:2346,1964.

210. Kutt, H., Wolk, M., Scherman, R., and McDowell, F., Insufficient parahydroxylation as cause of Dilantin toxicity, Neurology, 13: 356, 1963.

211. Kutt, H., Wolk, M., Scherman, R., and McDowell, F., Insufficient parahydroxylation as a cause of diphenylhydantoin toxicity, Neurology, 14: 542-548, 1964.

212. Lach, J.L.,Bhansali, K.,and Blaug, S.M.,The chromatographic separation and determination of diphenylhydantoin and phenobarbital, J. Amer. Pharm. Assn., 47: 48-49, 1958.

213. Laird, R. D. and Fonner, R. L., The protective effect of sodium diphenylhydantoin in the hyperacute radiation syndrome, U.S. Army Med. Res. Lab., Fort Knox, Kentucky, Report No. 262, 1957.

214. Lamberts, A. E., Tic douloureux, J. Mich. State Med. Soc., 58: 95-96, 1959.

215. Lang, T. W., Bernstein, H., Barbieri, F. F., Gold, H. and Corday, E., Digitalis toxicity: treatment with diphenylhydantoin, Arch. Intern. Med., 116: 573-580, 1965.

216. Laubscher, F. A., Fatal diphenylhydantoin poisoning: a case report, JAMA, 198; 1120-1121, 1966.

217. Lauriault, C. D. and Jim, R. T. S., Diphenylhydantoin toxicity; lymphadenopathy and low platelet count, Pediatrics, 37: 341-342, 1966.

218. Lefkowitz, M. M., Effects of diphenylhydantoin on disruptive behavior: study of male delinquents, Arch. Gen. Psychiat., 20: 643-651, 1969.

219. Lee, W. Y., Grummer, H. A., Bronsky, D., and Waldstein, S. S., Acute water loading as a diagnostic test for the inappropriate ADH syndromes, J. Lab. Clin. Med., 58: 937, 1961.

220. Lees, F., Radioactive vitamin B12 absorption in the megaloblastic anemia caused by anticonvulsant drugs, Quart. J. Med., 30: 231-248, 1961.

221. Leonard, W. A., Jr., The use of diphenylhydantoin (Dilantin) sodium in the treatment of ventricular tachycardia, A.M.A. Arch. Intern. Med., 101: 714-717, 1958.

222. Levitt, J. M. and Bionstein, M., Toxic amblyopia resulting from sodium diphenyl hydantoinate, New York J. Med., 40: 1538-1539, 1940.

223. Lieberson, A. D., Schumacher, R. R., Childress, R. H., Boyd, D. L., and Williams, J. F., Jr., Effect of diphenylhydantoin on left ventricular function in patients with heart disease, Circulation, 36: 692-699, 1967.

224. Lindblom, U., Diphenylhydantoin for trigeminal neuralgia, Svensk Lakartidn, 58: 3186-3191, 1961.

225. Lindsley, D. B. and Henry, C. E., The effect of drugs on behavior and the electroencephalograms of children with behavior disorders, Psychosom. Med., 4: 140-149, 1942.

226. Livingston, S., Petersen, D., and Boks, L. L., Hypertrichosis occurring in association with Dilantin therapy, J. Pediat., 47: 351-352, 1955.

227. Livingston, S. and Whitehouse, D., Treatment of headaches in children, Mod. Treatm., 1: 1391-1398, 1964.

228. Livingston, S., Whitehouse, D., and Pauli, L. L., Study of the effects of diphenylhydantoin sodium on the lungs, New Eng. Mod., 264: W-651, 1961.

229. Long, M. T., Childress, R. H., and Bond, W. H., Megaloblastic anemia associated with the use of anticonvulsant drugs: report of a case and review of the literature, Neurology, 13: 697-702,1963.

230. Louis, S., Kutt, H., and McDowell, F., The cardiocirculatory changes caused by intravenous Dilantin and its solvent, Amer. Heart J., 74: 523-529, 1967.

231. Louis, S., Kutt, H., and McDowell, F., Intravenous diphenylhydantoin in experimental seizures: 11. Effect on penicillin-induced seizures in the cat, Arch. Neurol., 18: 472-477, 1968.

232. Lovelace, R. E. and Horwitz, S. J., Peripheral neuropathy in long-term diphenylhydantoin therapy, Arch. Neurol., 18: 69-77, 1968.

233. L.kllmann, H. and Weber, R., On the action of Phenytoin on digitalis-induced arrhythmia, Arztliche Forschung, 22: 49-55, 1968.

234. Lustberg, A., Goldman, D., and Dreskin, 0. H., Megaloblastic anemia due to Dilantin therapy, Ann. Intem. Med., 54: 153-158, 1961.

235. McCullagh, W. M. and Ingram, W., Jr., Headaches and hot tempers, Dis. Nerv. Syst., 17: 279-281, 1956.

236. McDonald, D. B., Diphenylhydantoin and multiple system disease, Grace Hosp. Bull., 44: 40-44, 1966.

237. MacIntosh, P. C. and Hutchison, J. L., Megaloblastic anemia due to anticonvulsant therapy: report of a case responding to vitamin B12, Canad. Med. Assn. J., 82: 365-368, 1960.

238. Magee, K. R. and Wong, R. N., Complications of treatment and side reactions to anticonvulsant drugs, Mod. Treatm., I: 1138-1149,1964.

239. Malygina, E. H., Effect of phenobarbital, diphenylhydantoin and trimethadione on the blood sugar level (rabbit), Farmakol. Toksik., 28: 725-727, 1965.

240. Mandelbaum, H. and Kane, L. J., Dilantin sodium poisoning; report of a case with dermatitis exfoliativa, pyrexia and hepatic and splenic enlargement, Arch. Neurol. Psychiat., 45: 769-771, 1941.

241. Maniapaz, J. S., Abducens nerve palsy in Dilantin intoxication, J. Pediat., 55: 73-77, 1959.

242. Mark, V. H., Sweet, W. R., Ervin, F. R., Solomon, P., and Geschwind, N., Brain disease and violent behavior, Neurophthalmology, Chap. 20, 4: 282-287, J. L. Smith, ed., C. V. Mosby, St. Louis, 1968.

243. Marriott, H. J. L., Management of cardiac dysrhythmias complicating acute myocardial infarction, Geriatrics, 147-156, Sept., 1968.

244. Martin, C. M., Rubin, M., O’Malley, W. E., Garagusi, V. F., and McCauley, C. E., Comparative physiological availability of brand and generic drugs in man: chloramphenicol, sulfisoxazole, and diphenylhydantoin, Pharmacologist, 10: 167, 1968.

245. Massey, K. M., Teratogenic effects of diphenylhydantoin sodium, J. Oral Ther. Pharmacol., 2: 380-385, 1966.

246. Meeuwisse, G., Gamstorp, I., and Tryding, N., Effect of Phenytoin on the tryptophan load test, Acta Paediat. Scand., 57: 115-120, 1968.

247. Melchior, J. C. and Svensniark, O., A case of Phenytoin hypersensitivity, Acta Paediat. Scand., 52: 138-149, 1963.

248. Mercer, E. N. and Osborne, J. A., The current status of diphenylhydantoin in heart disease, Ann. Intern. Med., 67: 1084-1107, 1967.

249. Mercer, E. N., Ziegler, W. G., Wickland, G. F., and Dower, G. E., The effect of diphenylhydantoin upon beating of heart cells grown in vitro, J. Pharm. Exp. Ther., 155: 267-270, 1967.

250. Merritt, H. H. and Putnam, T. J., A new series of anticonvulsant drugs tested by experiments on animals, Arch. Neurol. Psychiat., 39: 1003-1015, 1938.

251. Mertens, H. G. and Zschocke, S., Neuromyotonia, Klin. Wschr., 17: 917-925, 1965.

252. Michels, J. G., Wright, G. C., and Gever, G., Synthesis and pharmacological activity of a series of 2-substituted pyridazinones, J. Med. Chem., 9: 612-615, 1966.

253. Middleton, J. W. and Hejtmancik, M. R., Severe leukopenia due to diphenylhydantoin sodium: case report, Texas State J. Med., 46: 520-521, 1950.

254. Millichap. J. G. and Boldrey, E. E., Studies in hyperkinetic behavior: II. Laboratory and clinical evaluations of drug treatments, Neurology, 17: 467-472, 1967.

255. Mixter, C. G., Moran, J. M., and Austen, W. G., Cardiac and peripheral vascular effects of diphenylhydantoin sodium, Amer. J. Cardiol., 17: 332-338, 1966.

256. Moore, M. T., Pulmonary changes. in hydantoin therapy, JAMA, 171: 1328-1333, 1959.

257. Morrell, F., Bradley, W., and Ptashne, M., Effect of diphenylhydantoin on peripheral nerve, Neurology, 8: 140-144, 1958.

258. Morrell, F., Bradley, W., and Ptashne, M., Effect of drugs on discharge characteristics of chronic epileptogenic lesions, Neurology, 9: 492-498, 1959.

259. Morris, J. V., Fischer, E., and Bergin, J. T., Rare complication of Phenytoin sodium treatment, Brit. Med. J.. 2: 1529, 1956.

260. Mosey, L. and Tyler, M. D., The effect of diphenylhydantoin sodium (Dilantin), procaine hydrochloride, procaine amide hydrochloride, and quinidine hydrochloride upon ouabain-induced ventricular tachycardia in unanesthetized dogs, Circulation, 10: 65-70, 1954.

261. Mull, J. D. and Mullinax, F., Diphenylhydantoin allergy: clinical and immunological studies, Arthritis Rheum., 9: 525-526, 1966.

262. Munsat, T. L., Therapy of myotonia: a double-blind evaluation of diphenylhydantoin, procainamide, and placebo, Neurology, 17: 359-367, 1967.

263. Naiman, J. G. and Williams, H. L., Effects of diphenylhydantoin on the duration of respiratory activity during anoxia, J. Pharm. Exp. Ther., 145: 34-41, 1964.

264. Nakamura, K. and Kurebe, M., Differential effects of antiepileptics on hippocampal and pallidal after discharges in cats, Jap. J. Pharmacol., 12: 180-190, 1962.

265. Nakamura, K. and Masuda, Y., Effects of 5,5-diphenylhydantoin  and   3-ethoxycarbonyl-5,5-diphenylhydantoin (P-6127) on the dermal and gingival tissues of experimental animals, Arch. Int. Pharmacodyn., 162: 255-264, 1966.

266. Nakamura, K., Masuda, Y., and Nakatsuji, K., Tissue distribution and metabolic fate of 3-ethoxycarbonyl-5,5-diphenylhydantoin (P-6127) and 5,5-diphenylhydantoin in rats, Arch. Int. Pharmacodyn., 165: 103-111, 1967.

267. Nakamura, K., Masuda, Y., Nakatsuji, K., and Hiroka, T., Comparative studies on the distribution and metabolic fate of diphenylhydantoin and 3-ethoxycarbonyl-diphenylhydantoin (P-6127) after chronic administrations to dogs and cats, Naunyn- Schmiedeberg Arch. Pharm., 254: 406-417, 1966.

268. Natelson, S., Walker, A. A., and Pincus, J. B., Chlordiazepoxide and diphenylhydantoin as antagonists to ACTH effect on serum calcium and citrate levels, Proc. Soc. Exp. Biol. Med., 122: 689-692,1966.

269. Noach, E. L., Woodbury, D. M., and Goodman, L. S., Studies on the absorption, distribution, fate and excretion of 4-C14-labeled diphenylhydantoin, J. Pharm. Exp. Ther., 122: 301-314, 1958.

270. Norris, F. H., Jr., Colella, J., and McFarlin, D., Effect of diphenythydantoin on neuromuscular synapse, Neurology, 14: 869-876,1964.

271. Oberst, B. B., Preventive care of infants and children. VI. School adjustment problems and their relationship to guided growth, J. Lancet, 86: 331-334, 1966.

272. Olesen, 0. V., Determination of phenobarbital and Phenytoin in serum by ultraviolet spectrophotometry, Scand. J. Clin. Lab. Invest., 20: 63-69, 1967.

273. Olesen, 0. V., Disulfiramum (Antabuse) as inhibitor of Phenytoin metabolism, Acta Pharmacol. Toxicol., 24: 317-322, 1966.

274. Olesen, 0. V., Determination of 5-(p-hydroxyphenyl)-5phenylhydantoin (HPPH) in urine by thin layer chromatography, Acta Pharmacol. Toxicol., 26: 222-228, 1968.

275. Olesen, 0. V., A simplified method for extracting Phenytoin from serum, and a more sensitive staining reaction for quantitative determination by thin layer chromatography, Acta Pharmacol. Toxicol., 25: 123-126, 1967.

276. Oppenheimer, J. H., Fisher, L. V., Nelson, K. M., and Jailer, J. W., Depression of the serum protein-bound iodine level by diphenylhydantoin, J. Clin. Endoc. Metab., 21: 252-262, 1961.

277. Orth, D. N., Almeida, H., Walsh, F. B., and Honda, M., Ophthalmoplegia resulting from diphenylhydantoin and primidone intoxication, JAMA, 201: 485-487, 1967.

278. Parrow, A., Use of anticonvulsive drugs in the treatment of recurrent cardiac arrhythmias, Atia Med. Scand., 180: 413-419, 1966.

279. Patil, K. P., Chitre, R. G., and Sheth, U. K., Anti-folic acid activity of anti-epileptic drugs: Part 1. Studies with bacterial cultures, Indian J. Med. Sci., 20: 614-622, 1966.

280. Pennington, G. W. and Smyth, D., Identification reactions of the hydantoin group of drugs, Arch. Int. Pharmacodyn., 152: 285-297, 1964.

281. Penny, J. L., Megaloblastic anemia during anticonvulsant drug therapy, Arch. intern. Med., 111: 744-749, 1963.

282. Peters, H. A., Eichman, P. L., Price, J. M., Kozelka, F. L., and Reese, H. H., Abnormal copper and tryptophan metabolism and chelation therapy in anti-convulsant drug intolerance, Dis. Nerv. Syst., 27: 97-106, 1966.

283. Petty, C. S., Muelling, R. J., and Sindell, H. W., Accidental, fatal poisoning with diphenylhydantoin (Ditantin), J. Forensic Sci., 2: 279-286, 1957.

284. Petty, W. C. and Karler, R., The influence of aging on the activity of anti-convulsant drugs, J. Pharm. Exp. Ther., 150: 443-448, 1965.

285. Pincus, J. H. and Giarman, N. J., The effect of diphenylhydantoin on sodium-, potassium-, magnesium-stimulated adenosine triphosphatase activity of rat brain, Biochem. Pharmacol., 16: 600-603, 1967.

286. Pincus, J. H. and Glaser, G. H., The syndrome of minimal brain damage in childhood. New Eng. J. Mod., 275: 27-35, 1966.

287. Putnam, T. J. and Hood, 0. E., Project Illinois: a study of therapy in juvenile behavior problems, Western Med., 231-233, July, 1964.

288. Raines, A. and Levitt, B., The failure of diphenylhydantoin to influence the B-adrenergic receptor of the heart, Arch. Int. Pharmacodyn., 172: 435-441, 1968.

289. Raines, A. and Standaert, F. G., Pre- and postjunctional effects of diphenylhydantoin at the cat soleus neuromuscular junction, J. Pharm. Exp. Ther., 153: 361-366, 1966.

290. Ramirez, E., The use of diphenylhydantoin in the modification of acting-out behavior of post-detoxification addict patients, Personal communication. 1967.

291. Rand, B. O., Kelly, W. A., and Ward, A. A., J r., Electrophysiological studies of the action of intravenous diphenylhydantoin (Dilantin), Neurology, 16: 1022-1032, 1966.

292. Rantakallio, P. and Furuhjelm, U., Diphenylhydantoin sensitivity: a case with exfoliative dermatitis and atypical lymphocytes in the peripheral blood, Ann. Paediat. Fenn., 8: 146-151, 1962.

293. Rawson, M. D. and Pincus, J. H., The effect of diphenylhydantoin on sodium, potassium, magnesium-activated adenosine triphosphatase in rnicrosomal fractions of rat and guinea pig brain and on whole homogenates of human brain, Biochem. Pharmacol., 17: 573-579, 1968.

294. Recant, L. and Hartroft, W. S., Lymphoma or drug reaction occurring during hydantoin therapy for epilepsy, Amer. Med., 321: 286-297, 1 962.

295. Reichelderfer, T. E., Pearson, P. H., and Livingston, S., Thrombocytopenic purpura occurring in association with paradione (paramethadione) and Dilantin sodium (Phenytoin sodium) therapy, J. Pediat., 43: 43-46, 1953.

296. Remmer, H., Estabrook, R. W., Schenkman, J., and Greim, H., Reaction of drugs with microsomal liver hydroxylase: its influence on drug action, Naunyn-Schmiedeberg Arch. Pharm., 259: 98-116, 1968.

297. Resnick, O., The psychoactive properties of diphenylhydantoin: experiences with prisoners and juvenile delinquents, Int. J. Neuropsychiat. 3: S30-S48, 1967.

298. Livingston, S., Treatment of epilepsy with diphenylhydantoin sodium (Dilantin sodium), Post-grad. Med., 20: 584-590, 1956.

299. Reynolds, E. H., Effects of folk acid on the mental state and fit-frequency of drug-treated epileptic patients, Lancet, 1: 1086-1088, 1967.

300. Reynolds, E. H., Mental effects of anticonvulsants, and folic acid metabolism, Brain, 91: 197-214, 1968.

301. Rhind, E. G. and Varadi, S., Megaloblastic anemia due to Phenytoin sodium, Lancet, 2: 921, 1954.

302. Rinne, U. K., Effect of diphenylhydantoin treatment on the release of corticotrophin in epileptic patients, Confin. Neurol., 27: 431-440, 1966.

303. Rinne, U. K., Site of the inhibiting action of diphenylhydantoin on the release of corticotrophin in epileptic patients, Med. Pharmacol. Exp., 17: 409-416, 1967.

304. Roberts, H. J., On the etiology, rational treatment and prevention of multiple sclerosis, Southern Med, J., 59: 940-950, 1966.

305. Robinow, M., Diphenylhydantoin hypersensitivity: treatment with 6-mercaptopurine, Amer. J. Dis. Child., 106: 553-557, 1963.

306. Robinson, D. S., MacDonald, M. G., and Hobin, F. P., Sodium diphenylhydantoin reaction with evidence of circulating antibodies, JAMA, 192: 171-172, 1965.

307. Robinson,L.J., The gingival changes produced by Dilantin sodium, Dis. Nerv. Syst., 3: 88-94, 1942.

308. Rosati, R. A., Alexander, J. A., Schaal, S. F., and Wallace, A. G., Influence of diphenylhydantoin on electrophysiological properties of the canine heart, Circ. Res., 21: 757-765, 1967.

309. Roseman, E., Dilantin toxicity: a clinical and electroencephalographic study, Neurology, II: 912-921, 196 1.

310. Rosen, M., Lisak, R., and Rubin, 1. L., Diphenylhydantoin in cardiac arrhythmias, Amer. J. Cardiol., 20: 674-678, 1967.

311. Rosenberg, P. and Bartels, E., Drug effects on the spontaneous electrical activity of the squid giant axon, J. Pharm. Exp. Ther., 155: 532-544, 1967.

312. Rosenfeld, S., Swiller, A. I., Shenoy, Y. M. V., and Morrison, A. N., Syndrome simulating lymphosarcoma induced by diphenylhydantoin sodium, JAMA, 176: 491-493, 1961.

313. Ross, A. T. and Jackson, V., Dilantin sodium: its influence on conduct and on psychometric ratings of institutionalized epileptics, Ann. Intern. Med., 14: 770-773, 1940.

314. Rossi, A. O., Psychoneurologically impaired child: community mental health clinic approach, New York J. Med., 67: 902-912, 1967.

315. Rowntree, L. G. and Waggoner, R. W., Prevention of migraine attacks by Dilantin sodium, Dis. Nerv. Syst., 11: 148, 1950.

316. Rudzik, A. D. and Mennear, J. H., Antagonism of anticonvulsants by adrenergic blocking agents, Proc. Soc. Exp. Biol. Med., 122: 278-280, 1966.

317. Rushton, J. G., Medical treatment of trigeminal neuralgia with a note on the results of alcohol injection, Med. Clin. N. Amer., 52: 797-800, 1968.

318. Ruthen, G. C., Antiarrhythmic drugs: Part IV. Diphenylhydantoin in cardiac arrhythmias, Amer. Heart J., 70: 275-278, 1965.

319. Ryan, G. M. S. and Forshaw, J. W. B., Megaloblastic anemia due to Phenytoin sodium, Brit. Med. J., 2: 242-243, 1955.

320. Sack, L. P., The effects of sodium Dilantin on stuttering behavior, Univ. of Calif., L. A. Doctoral thesis, 1968.

321. Said, D. M., Fraga, J. R., and Reichelderfer, T. E., Hyperglycemia associated with diphenylhydantoin (Dilantin) intoxication, Med. Ann. D.C., 37: 170-172, 1968.

322. Saltzstein, S. L. and Ackerman, L. V., Lymphadenopathy induced by anti-convulsant drugs and mimicking clinically and pathologically malignant lymphomas, Cancer, 12: 164-182, 1959.

323. Sanbar, S. S., Conway, F. J., Zweifler, A. J., and Smet, G., Diabetogenic effect of Dilantin (diphenylhydantoin), Diabetes, 16: 533, 1967.

324. Sandberg, D. H., Resnick, G. L., and Bacallao, C. Z., Measurement of serum diphenylhydantoin by gas-liquid chromatography, Anal. Chem., 40: 736-738,1968.

325. Sasyniuk, B. 1. and Dresel, P. E., The effect of diphenylhydantoin on conduction in isolated, blood-perfused dog hearts, J. Pharm. Exp. Ther., 161: 191-196, 1968.

326. Schaaf, M. and Payne, C. A., Effect of diphenylhydantoin and phenobarbital on overt and latent tetany, New Eng. J. Med., 274: 1228-1233, 1966.

327. Scherlag, B. J., Helfant, R. H., and Damato, A. N., The contrasting effects of diphenylhydantoin and procaine amide on A-V conduction in the digitalis-intoxicated and the normal heart, Amer. Heart J., 75: 200-205, 1968.

328. Scherlag, B. J., Helfant, R. H., and Damato, A. N., The relationship between the ionic, inotropic and electrophysiological effects of digitalis, Circulation, 36; 230, 1967.

329. Schneider, E., Treatment of dysrhythmic migraine and other forms of cephalagia with a new combinative preparation (Sanredo), Schweiz. Med. Wschr., 37: 1340-1343, 1963.

330. Schdn, A., Treatment with diphenylhydantoin in essential trigeminal neuralgia and in facial spasm, Gior. Psichiat. Neuropat., 92: 1011-1020, 1964.

331. Schönhärl, E., Pharmacotherapeutic experiences in speech and vocal disturbances, Med. Exp., 2: 179-183, 1960.

332. Schulte, C. J. A., and Good, T. A., Acute intoxication due to methsuximide and diphenylhydantoin, J. Pediat., 68: 635-637, 1966.

333. Schwab, R. S., Timberlake, W. H., and Abbott, J. A., Control of side effects of anticonvulsant drugs, Med. Clin. N. Amer., Boston Number, 1139-1150, 1954.

334. Serrate, J. P., Contribution to the treatment of chorea minor by diphenylhydantoin, Gac. Med. Espan., 21; 160-161, 1947.

335. Shafer, W. G., The effect of Dilantin sodium on liver DNA and restitution, J. Oral Ther. Pharm., 2: 319-323, 1966.

336. Shafer, W. G., Response of radiated human gingival fibroblast-like cells to Dilantin sodium in tissue culture, J. Dent. Res., 44: 671-677, 1965.

337. Shafer, W. G., Beatty, R. E., and Davis, W. B., Effect of Dilantin sodium on tensile strength of healing wounds, Proc. Soc. Exp. Biol, 98: 348-350, 1958.

338. Shapera, W., Dilantin therapy in certain nervous disorders, Pittsburgh Med. Bull., 29: 732-736, 1940.

339. Shapiro, M., Acceleration of gingival wound healing in non-epileptic patients receiving diphenylhydantoin sodium, Exp. Med. Surg., 16: 41-53, 1958.

340. Shulman, A. and Laycock, G. M., Action of central nervous system stimulant and depressant drugs in the intact animal: Part 3. Dual action of 5-ethyl-5-(1,3-dimethylbutyl) barbiturate, Dilantin and B-methyl-B-n-propylglutarimide, Europ. J. Phamacol., 2: 17-25, 1967.

341. Shulman, M. H., The use of Dilantin sodium in bronchial asthma: a preliminary report, New Eng. J. Med., 226: 260-264, 1942.

342. Siegel, S. and Berkowitz, J., Diphenylhydantoin (Dilantin) hypersensitivity with infectious mononucleosis-like syndrome and jaundice, J. Allergy, 32: 447-451, 1961.

343. Sklans, S., Taylor, R. G., and Shklar, G., Effect of diphenylhydantoin sodium on healing of experimentally produced fractures  in rabbit mandibles, J. Oral Surg., 25: 310-319, 1967.

344. Simpson, G. M., Kunz, E., and Slafta, J., Use of sodium diphenylhydantoin in treatment of leg ulcers, New York J. Med., 65: 886-888, 1965.

345. Simpson, W., Severe megaloblastic anemia induced by Phenytoin sodium, Oral Surg., 22: 302-305, 1966.

346. Smith, I. M., Lindell, S. S., Hazard, E. C., and Rabinovich, S., Chemical treatments of staphylococcal infections in mice, Nature, 211: 720-722, 1966.

347. Snyder, C. H., Syndrome of gingival hyperplasia, hirsutism, and convulsions: Dilantin intoxication without Dilantin, Pediat., 67: 499-502, 1965.

348. Solomon, H. M. and Schrogie, J. J., The effect of phenylramidol on the metabolism of diphenylhydantoin, Clin. ,Pharm. Ther., 8: 554-556, 1967.

349. Sparberg, M., Diagnostically confusing complications of diphenylhydantoin therapy: a review, Ann. Intem. Med., 59: 914-930,1963.

350. Standish, S. M. and Clark, P. G., The effect of Dilantin sodium on connective tissue generation in polyvinyl sponge implants, Transplantation Bull., 29: 439-445, 1962.

351. Stevens, H., Paroxysmal choreo-athetosis: a form of reflex epilepsy, Arch. Neurol., 14: 415-420, 1966.

352. Stille, G., On the question of the action of diphenylhydantoin in states of pain: a neurophysiological analysis, Nervenarzt, 31: 109-112, 1960.

353. Swan, H. and Sawyer, D. C., Prevention of ventricular fibrillation during experimental hypothermia: failure of sodium diphenylhydantoin, Arch. Surg., 95: 23-26,1967.

354. Swerdlow, B., Acute brain syndrome associated with sodium diphenylhydantoin intoxication, Amer. J. Psychiat., 122: 100-101, 1965.

355. Tec, L., Efficacy of diphenylhydantoin in childhood psychiatric disorders, Amer. J. Psychiat., 124: 156-157, 1968.

356. Theopold, W., On the use of hydantoin derivatives in chorea minor, Zschr. Kinderh., 69: 305-310, 1951.

357. Tichner, J. B. and Enselberg, C. D., Suicidal Dilantin (sodium diphenylhydantoin) poisoning, New Eng. J. Med., 245: 723-725, 1951.

358. Toman, J. E. P., Neuropharmacologic considerations in psychic seizures, Neurology, 1: 444-460, 195 1.

359. Toman, J. E. P., Drugs effective in convulsive disorders, The Pharmacological Basis of Therapeutics, 3rd Ed., 215-224, Goodman, L. S., Gilman, A., Eds., Macmillan, New York, 1965.

360. Tompsett, S. L., Note on the detection of hexoestrol, stilboestrol, dienoestrol and the p-hydroxy metabolites of phenobarbitone and Phenytoin in urine, J. Pharm. Pharmacol., 16: 207-208, 1964.

361. Triedman, H. M., Fishman, R. A., and Yahr, M. D., Determination of plasma and cerebrospinal fluid levels of Dilantin in the human, Trans. Amer. Neurol. Assn., 85: 166-170, 1960.

362. Turner, W. J., Anticonvulsive agents in the treatment of aggression, Proc. Symp. Aggressive Behavior, Milan, May 1968, 353-362, S. Garattini and E. B. Sigg, Eds., Excerpta Medica, Amsterdam, 1969.

363. Turner, W. J., Therapeutic use of diphenylhydantoin in neuroses, Int. J. Neuropsychiat., 3: 94-105, 1967.

364. Turner, W. J., The usefulness of diphenylhydantoin in treatment of non-epileptic emotional disorders, Int. J. Neuropsychiat., 3: suppl. 2, S8-S20, 1967.

365. Tuttle, R. S., and Preston, J. B., The effects of diphenylhydantoin (Dilantin) on segmental and suprasegmental facilitation and inhibition of segmental motoneurons in the cat, J. Pharm. Exp. Ther., 141: 84-91, 1963.

366. Ungar, B. and Cowling, D. C., Megaloblastic anemia associated with anticonvulsant drug therapy, Med. J. Aust., 2: 461 -462, 1960.

367. Unger, A. H. and Sklaroff, H. J., Fatalities following intravenous use of sodium diphenylhydantoin for cardiac arrhythmias: report of two cases, JAMA, 200: 335-336, 1967.

368. van Wyk, J. J. and Hoffmann, C. R., Periarteritis nodosa: a case of fatal exfoliative dermatitis resulting from “Dilantin sodium” sensitization, Arch. Intern. Med., 81: 605-611, 1948.

369. Vasko, J. S., Elkins, R. C., Fogarty, T. J., and Morrow, A. G., Effects of diphenylhydantoin on cardiac performance and peripheral vascular resistance, Surg. Forum, 17: 189-190, 1966.

370. Vastola, E. F. and Rosen, A., Suppression by anticonvulsants of focal electrical seizures in the neocortex, Electroenceph. Clin. Neurophysiol., 12: 327-332, 1960.

371. Vernadakis, A. and Woodbury, D. M., Effects of cortisol and diphenylhydantoin on spinal cord convulsions in developing rats, J.,Pharm. Exp. Ther., 144: 316-320, 1964.

372. Vincent, M. C. and Blake, M. I., A note on the analysis of diphenylhydantoin sodium by an ion exchange procedure, Drug Standards, 26: 206-207, 1958.

373. Walker, C. F. and Kirkpatrick, B. B., Dilantin treatment for behavior problem children with abnormal electroencephalograms, Amer. J. Psychiat., 103: 484-492, 1947.

374. Wallace, J., Biggs, J., and Dahl, E. V., Determination of diphenylhydantoin by ultraviolet spectrophotometry, Anal. Chem., 37: 410-413,1965.

375. Walsh, P. 1. F., Prophylaxis in alcoholics in the withdrawal period, Amer. J. Psychiat., 119: 262-263, 1962.

376. Weintraub, R. M., Pechet, L., and Alexander, B., Rapid diagnosis of drug-induced thrombocytopenic purpura, JAMA, 180: 528-532,1962.

377. Werk, E. E., Jr., MacGee, J., and Sholiton, L. J., Effect of diphenylhydantoin on cortisol metabolism in man, J. Clin. Invest., 43: 1824-1835, 1964.

378. Werk, E. E., Jr., Thrasher, K., Choi, Y., and Sholiton, L. J., Failure of metyrapone to inhibit 11-hydroxylation of 11 deoxycortisol during drug therapy, J. Clin. Endoc. Metab., 27: 1358-1360, 1967.

379. Westerink, D., Chromatographic separation and microdetermination of phenobarbital, methylphenobarbital, butobarbital and Phenytoin, Pharm. Weekbl., 97: 849-856, 1962.

380. Weidemann, D. H., New viewpoints on migraine therapy, Med. Mschr., 20: 28-30, 1966.

381. Wilske, K. R., Shalit, 1. E., Willkens, R. F., and Decker, L., Findings suggestive of systemic lupus crythematosus in subjects on chronic anticonvulsant therapy, Arthritis Rheum., 8: 260-266, 1965.

382. Wilson, D. R., Electroencephalographic studies in diabetes mellitus, Canad. Med. Assn., J., 65: 462-465, 1951.

383. Wilhoit, W. M. C., The broader treatment of acute alcoholism and delirium tremens, J. Florida Med. Assn., 52: 254-255, 1965.

384. Winiker-Blanck, E., On the diphenylhydantoin therapy of trigeminal neuralgia, Deutsch Stomat., 5: 321-322, 1955.

385. Ichikawa, J., Kimura, E., Terui, H., Wada, T., Sakurada, T., and Sakurada, S., Biochemical studies on antiepileptic drugs. 1. Effect on glucose metabolism in guinea pig brain slices, Seishin Shinkeigaku Zasshi, 69: 1089-1100, 1967.

386. Wolnisty, C., Polyneuritis of pregnancy effectively managed with Dilantin: report of a case, Obstet. Gynec., 23: 802-803, 1964.

387. Woodbury, D. M., Effect of diphenylhydantoin on electrolytes and radiosodium turnover in brain and other tissues of normal, hyponatremic and postictal rats, J. Pharm. Exp. Ther., 115: 74-95, 1955.

388. Woodbury, D. M., Effect of diphenylhydantoin on pentylene tetrazol-induced seizures in developing rats, Pharmacologist, 8: 176, 1966.

389. Woodbury, D. M. and Esplin, D. W., Neuropharmacology and neurochemistry of anticonvulsant drugs, Proc. Assn. Res. Nerv. Ment. Dis., 37: 24-57, 1959.

390. Yunis, A. A., Arimura, G. K., Lutcher, C. L., and Blasquez, J., Reversible crythroid aplasia induced by Dilantin: mechanism of action of Dilantin, J. Lab. Clin. Med., 64: 1021, 1964.

391. Yunis, A. A., Arimura, G. K., Lutcher, C. L., Blasquez, and Halloran, M., Biochemical lesion in Dilantin-induced crythroid aplasia, Blood, 30: 587-600, 1967.

392. Zeft, H. J., Whalen, R. E., Ratliff, N. B., Jr., Davenport, R. D., Jr., and McIntosh, H. D., Diphenylhydantoin therapy in experimental myocardial infarction,